Key facts
- This page summarizes Alan Colman's Form 4 filing for VOLITIONRX LTD (VNRX).
- 2 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 08 Apr 2022, 16:04.
Key filing fact
Ownership activity is grounded in SEC Form 4 disclosures.
Shares, units, or other non-derivative securities reported in this filing.
Award
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
Award
Additional SEC filing notes
Footnote F1
On August 3, 2021, the reporting person was awarded 7,029 restricted stock units, subject to vesting upon achievement of certain corporate performance goals on or prior to July 1, 2022 and also subject to time-based vesting. Certain of the performance goals were met, resulting in the rights with respect to 2,460 restricted stock units vesting. The restricted stock units are further subject to a 2-year time-based vesting schedule, vesting in two equal installments of 1,230 units on each of August 3, 2022 and August 3, 2023, respectively. Upon vesting and settlement, the reporting person will receive a number of shares of common stock equal to the number of restricted stock units that have vested.
Footnote F2
On August 3, 2021, the reporting person was granted an option to purchase 12,953 shares of common stock, subject to vesting upon achievement of certain corporate performance goals on or prior to July 1, 2022 and also subject to time-based vesting. Certain of the performance goals were met, resulting in the rights with respect to 4,533 shares vesting. The vested shares are further subject to a 2-year time based vesting schedule, vesting in two installments of 2,266 shares and 2,267 shares on each of August 3, 2022 and August 3, 2023, respectively.